ANIX Anixa Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIX

Price (delayed)

$3.1

Market cap

$98.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.34

Enterprise value

$98.05M

Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type ...

Highlights
The debt has decreased by 22% YoY and by 7% from the previous quarter
The company's quick ratio fell by 36% YoY but it rose by 23% QoQ
ANIX's EPS is up by 17% year-on-year but it is down by 6% since the previous quarter
The equity has contracted by 11% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.anixa.com
Peers: OCX OGEN OLMA OMER

Key stats

What are the main financial stats of ANIX
Market
Shares outstanding
31.9M
Market cap
$98.89M
Enterprise value
$98.05M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.99
Price to sales (P/S)
464.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
466.92
Earnings
Revenue
$210,000
EBIT
-$10.74M
EBITDA
-$10.7M
Free cash flow
-$6.53M
Per share
EPS
-$0.34
Free cash flow per share
-$0.21
Book value per share
$0.78
Revenue per share
$0.01
TBVPS
$0.81
Balance sheet
Total assets
$25.37M
Total liabilities
$1.77M
Debt
$162,000
Equity
$24.61M
Working capital
$23.56M
Liquidity
Debt to equity
0.01
Current ratio
15.19
Quick ratio
14.57
Net debt/EBITDA
0.08
Margins
EBITDA margin
-5,093.3%
Gross margin
23.3%
Net margin
-5,116.2%
Operating margin
-5,744.8%
Efficiency
Return on assets
-40.9%
Return on equity
-42.4%
Return on invested capital
-48.8%
Return on capital employed
-45.3%
Return on sales
-5,116.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIX stock price

How has the Anixa Biosciences stock price performed over time
Intraday
1.64%
1 week
-3.73%
1 month
-11.68%
1 year
-32.61%
YTD
-20.1%
QTD
-0.64%

Financial performance

How have Anixa Biosciences's revenue and profit performed over time
Revenue
$210,000
Gross profit
$49,000
Operating income
-$12.06M
Net income
-$10.74M
Gross margin
23.3%
Net margin
-5,116.2%
The net income has increased by 11% year-on-year but it has declined by 10% since the previous quarter
ANIX's operating margin is down by 10% QoQ
The net margin has decreased by 10% from the previous quarter
ANIX's operating income is down by 10% since the previous quarter but it is up by 3.9% year-on-year

Growth

What is Anixa Biosciences's growth rate over time

Valuation

What is Anixa Biosciences stock price valuation
P/E
N/A
P/B
3.99
P/S
464.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
466.92
ANIX's EPS is up by 17% year-on-year but it is down by 6% since the previous quarter
The price to book (P/B) is 41% lower than the 5-year quarterly average of 6.8 and 15% lower than the last 4 quarters average of 4.7
The equity has contracted by 11% YoY
The P/S is 18% less than the last 4 quarters average of 569.1

Efficiency

How efficient is Anixa Biosciences business performance
Anixa Biosciences's return on invested capital has surged by 55% YoY but it has decreased by 2.7% QoQ
The company's return on assets fell by 13% QoQ and by 4.9% YoY
The return on equity has declined by 13% since the previous quarter and by 6% year-on-year
ANIX's return on sales is down by 10% since the previous quarter

Dividends

What is ANIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIX.

Financial health

How did Anixa Biosciences financials performed over time
The company's quick ratio fell by 36% YoY but it rose by 23% QoQ
The current ratio has declined by 33% year-on-year but it rose by 22% since the previous quarter
The debt is 99% less than the equity
The debt has decreased by 22% YoY and by 7% from the previous quarter
The equity has contracted by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.